Professional Documents
Culture Documents
Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez AP, Cao C, Kupfer S
J Clin Hypertens. 2011;13:81-88
Disclosures
EU/AZI-010002
Hypertension has been identified as the leading risk factor for mortality worldwide1
Hypertension affects approximately 44% of people aged 35-64 years and remains poorly controlled3
For every 20mmHg increase in clinical SBP or 10mmHg clinical DBP, the risk of vascular mortality doubles4 Cardiovascular disease costs Europe an estimated 169 billion each year2, with hypertension a major modifiable risk factor Modest reductions in SBP can substantially reduce morbidity and mortality of vascular events5
% Reduction in mortality Reduction in SBP (mmHg) Stroke CHD Total
2
3
-6
-8
-4
-5
-3
-4
-14
-9
-7
SBP = systolic blood pressure; DBP=diastolic blood pressure; CHD=coronary heart disease
1. Ezzati et al. Lancet. 2002;360:134760. 2. Leal J, et al. Eur Heart J 2006;27:1610-19. 3. Wolf-Maier K, et al. JAMA 2003;289:2363-2369. 4. Lewington S, et al. Lancet. 2002;360:19031913. 5. Whelton PK, et al. JAMA 2002;288:1882-1888.
EU/AZI-010002
O O H 3C O OOC N OCH2CH3
N O
NH
O
N TAK-491 MW=606.62
Hydrolysis
N OCH2CH3 N
NH O
TAK-536 MW=456.46
1. Veronesi M, et al. Vasc Health Risk Manag 2007;3:999-1005 2. Bakris GL, et al. J Clin Hypertens 2011;13:81-88.
EU/AZI-010002
Washout
AZL-M 40 mg (n=283)
AZL-M 80 mg (n=285)
OLM-M 40 mg (n=282)
PLACEBO (n=142)
Screening
1 week
2 weeks
6 weeks
AZL-M = azilsartan medoxomil, OLM-M = olmesartan medoxomil Bakris GL, et al. J Clin Hypertens 2011;13:81-88.
EU/AZI-010002
Severe renal impairment or known/suspected renal artery stenosis Type 1 or poorly controlled type 2 diabetes
Significant hepatic abnormalities Hyperkalaemia
CVD = cardiovascular disease, SBP = systolic blood pressure, DBP = diastolic blood pressure
Bakris GL, et al. J Clin Hypertens 2011;13:81-88.
EU/AZI-010002
Study endpoints
Primary endpoint:
Mean change in 24-hour mean SBP (by ABPM) at 6 weeks
Safety endpoints:
Adverse events
Laboratory tests
ECG
Vital signs
Other:
Mean change in 24-hour DBP by ABPM Mean change in trough sitting clinic DBP Day-time mean (6 am10 pm), night-time mean (12 am6 am), mean at 0-12 hours after dosing, mean trough (22 24 hours after dosing) SBP and DBP
Proportion of responders*
*Response defined as clinic SBP <140 mmHg and/or reduction 20 mmHg from baseline Bakris GL, et al. J Clin Hypertens 2011;13:81-88.
EU/AZI-010002
Statistical analysis
Changes in 24-hour mean SBP and clinic SBP were analysed by a step-wise testing procedure (ANCOVA)
if the treatments failed to meet significance at one step, then analysis of the remaining steps became invalid
Other secondary variables used similar ANCOVA model without step-wise testing
EU/AZI-010002
83.4 (19.0)
30.0 (4.9)
84.2 (21.5)
30.4 (5.7)
84.6 (20.4)
30.6 (5.9)
83.5 (19.6)
30.0 (5.5)
82.9 (19.6)
29.8 (5.3)
76 (53.5) 66 (46.5)
Ethnicity, n (%)*
Caucasian Black/African-American American Indian/Alaska Native 103 (72.5) 16 (11.3) 29 (20.4) 202 (71.4) 32 (11.3) 51 (18.0) 205 (72.4) 31 (11.0) 49 (17.3) 209 (73.3) 31 (10.9) 52 (18.2) 209 (74.1) 31 (11.0) 50 (17.7)
* Rest Asian or multiracial; patients may have chosen more than one category for race
EU/AZI-010002
Placebo 24-hour mean BP, mmHg/n SBP (SD) DBP (SD) Clinic BP, mmHg/n SBP (SD) DBP (SD) 142 146.0 (12.5) 87.2 (9.4) 142 158.7 (11.4) 91.3 (10.4)
AZL-M 20 mg 282 145.6 (9.7) 87.6 (9.2) 283 158.7 (11.6) 92.4 (10.4)
AZL-M 40 mg 281 146.2 (10.2) 88.0 (9.2) 281 158.5 (12.2) 92.2 (11.2)
AZL-M 80 mg 282 146.3 (9.9) 87.7 (8.8) 284 159.4 (12.0) 92.1 (10.3)
EU/AZI-010002
10
Significantly greater reduction in 24-hour mean SBP at Week 6 with AZL-M 80 mg vs OLM-M 40 mg
Placebo
AZL-M 20mg
Baseline: 146.3 mmHg N=120
AZL-M 40mg
AZL-M 80mg
OLM-M 40mg
2 -2
-1.4
-6
-10
-14
-18
*p<0.001 vs placebo
-12.6*
p=0.038 vs OLM-M
EU/AZI-010002
11
Greater numerical reduction in trough clinic SBP at Week 6 with AZL-M 80 mg vs OLM-M 40 mg
Placebo
AZL-M 20mg
Baseline: 158.7mmHg N=140
AZL-M 40mg
AZL-M 80mg
OLM-M 40mg
0
-4 -8 -12 -16
-2.1
-14.3*
-14.5* -17.6*
-14.9*
-20
*p<0.001 vs placebo; Superiority of AZL-N 80 mg vs OLM-M 40 mg could not be claimed because prior step in sequential testing was not statistically significant.
Bakris GL, et al. J Clin Hypertens 2011;13:81-88.
EU/AZI-010002 12
Reductions in ambulatory SBP were sustained throughout the 24-hour monitoring period
5
EU/AZI-010002
13
AZL-M 40 mg
N=284 N=282
2 0.2
N=283 N=281 N=284 N=282 N=142
-0.7
-2
-2
-6
-6
-7.5* -8.4* -8.6* -7.7* -6.8* -6.9* -8.4* -6.9*
-10
*P<0.001 vs placebo
-10
P=0.172 vs OLM-M
*P<0.001 vs placebo
P=0.044 vs OLM-M
TPEU Data on file EU/AZI-010025 Adapted from Bakris G L, et al. J Clin Hypertens 2011; 13:81-88
EU/AZI-010002 14
OLM 40mg
53.2
N=282
60
Responders* (%)
50
40 30
47.8
N=283
50.4
N=281
N=284
20
10 0
*Reduction in clinic SBP to <140 mmHg and/or 20 mmHg decrease from baseline
EU/AZI-010002 15
Placebo (n=142)
51 (35.9)
6 (4.2) 3 (2.1) 0
EU/AZI-010002
16
Study summary
Efficacy (at Week 6)
AZL-M 80 mg lowered 24-hour mean SBP to a significantly greater extent than OLM-M 40 mg (-14.6 mmHg vs -12.6 mmHg; p=0.038) AZL-M 40 mg was non-inferior to OLM-M 40 mg
EU/AZI-010002 17
An important aspect of this trial is the use of ABPM to establish the primary end point. ABPM provides more reliable predictive data on cardiovascular outcomes than conventional office readings1 ...Data from this study suggest that AZL-M 80 mg is more effective in reducing SBP than the highest approved dose of OLM-M, which is considered to be more effective than others in the ARB class2,3
1. Bakris GL, et al. J Clin Hypertens 2011;13:81-88. 2. Zannad F, et al. Fundam Clin Pharmacol 2007;21:181-190. 3. Oparil S, et al. J Clin Hypertens 2001;3:283-291.
EU/AZI-010002 18
EU/AZI-010002 19